Published in Lab Law Weekly, June 16th, 2006
"The epidermal growth factor receptor (EGFR) is commonly overexpressed in many human tumors including gastrointestinal tract tumors. Gefitinib is a selective inhibitor of EGFR tyrosine kinase, and blocks several signal transduction pathways including those involved in tumor cell proliferation, angiogenesis and metastasis," scientists writing in the journal Oncology Reports explained.
"Recent mutational and biological studies have suggested that mutations in the tyrosine kinase domain of the EGFR gene are well correlated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly